DE69924500D1 - Chinazolinderivate - Google Patents
ChinazolinderivateInfo
- Publication number
- DE69924500D1 DE69924500D1 DE69924500T DE69924500T DE69924500D1 DE 69924500 D1 DE69924500 D1 DE 69924500D1 DE 69924500 T DE69924500 T DE 69924500T DE 69924500 T DE69924500 T DE 69924500T DE 69924500 D1 DE69924500 D1 DE 69924500D1
- Authority
- DE
- Germany
- Prior art keywords
- compounds
- useful
- prevent
- treat
- well
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/93—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9735998P | 1998-08-21 | 1998-08-21 | |
US9736598P | 1998-08-21 | 1998-08-21 | |
US97359P | 1998-08-21 | ||
US97365P | 1998-08-21 | ||
PCT/US1999/019043 WO2000010981A1 (en) | 1998-08-21 | 1999-08-20 | Quinazoline derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69924500D1 true DE69924500D1 (de) | 2005-05-04 |
DE69924500T2 DE69924500T2 (de) | 2006-02-09 |
Family
ID=26793164
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69924500T Expired - Fee Related DE69924500T2 (de) | 1998-08-21 | 1999-08-20 | Chinazolinderivate |
Country Status (13)
Country | Link |
---|---|
US (4) | US6313129B1 (de) |
EP (1) | EP1105378B1 (de) |
JP (1) | JP2002523403A (de) |
KR (1) | KR20010089171A (de) |
AT (1) | ATE292121T1 (de) |
AU (1) | AU5682799A (de) |
CA (1) | CA2342503A1 (de) |
DE (1) | DE69924500T2 (de) |
HU (1) | HUP0103386A3 (de) |
IL (1) | IL141434A0 (de) |
MX (1) | MXPA01001893A (de) |
NO (1) | NO20010887L (de) |
WO (1) | WO2000010981A1 (de) |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
AU3951899A (en) | 1998-06-19 | 2000-01-05 | Pfizer Products Inc. | Pyrrolo(2,3-d)pyrimidine compounds |
MXPA01001893A (es) * | 1998-08-21 | 2002-04-24 | Parker Hughes Inst | Derivados de quinazolina. |
WO2000044774A2 (en) * | 1999-01-27 | 2000-08-03 | The University Of South Florida | Inhibition of stat3 signal transduction for human cancer therapy |
US6080747A (en) | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
US6126917A (en) * | 1999-06-01 | 2000-10-03 | Hadasit Medical Research Services And Development Ltd. | Epidermal growth factor receptor binding compounds for positron emission tomography |
AP1905A (en) | 1999-12-10 | 2008-10-20 | Pfizer Prod Inc | Pyrrolo[2,3-d] Pyrimidine Compounds. |
UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
UA74370C2 (uk) | 2000-06-26 | 2005-12-15 | Пфайзер Продактс Інк. | Піроло(2,3-d)піримідинові сполуки як імуносупресори |
PL202812B1 (pl) | 2000-08-21 | 2009-07-31 | Astrazeneca Ab | Pochodna chinazoliny, jej kompozycja famaceutyczna oraz jej zastosowanie |
US20040052762A1 (en) * | 2001-09-10 | 2004-03-18 | Hua Yu | Stat3 agonists and antagonists and therapeutic uses thereof |
BR0114020A (pt) * | 2000-09-20 | 2003-07-22 | Merck Patent Gmbh | 4-amino-quinazolinas |
AUPR279101A0 (en) * | 2001-01-30 | 2001-02-22 | Cytopia Pty Ltd | Protein kinase signalling |
ATE325795T1 (de) * | 2001-03-23 | 2006-06-15 | Bayer Corp | Rho-kinase inhibitoren |
JP4320705B2 (ja) * | 2001-03-23 | 2009-08-26 | バイエル コーポレイション | Rhoキナーゼ阻害剤 |
SE0101675D0 (sv) | 2001-05-11 | 2001-05-11 | Astrazeneca Ab | Novel composition |
US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
US7829566B2 (en) * | 2001-09-17 | 2010-11-09 | Werner Mederski | 4-amino-quinazolines |
GB0122914D0 (en) * | 2001-09-22 | 2001-11-14 | Univ Nottingham | Modulation of stat activity |
WO2003046207A2 (en) | 2001-11-27 | 2003-06-05 | Fred Hutchinson Cancer Research Center | Methods for inhibiting deacetylase activity |
US20040014755A1 (en) * | 2002-01-10 | 2004-01-22 | Dhanapalan Nagarathnam | Rho-kinase inhibitors |
JP4469179B2 (ja) * | 2002-01-23 | 2010-05-26 | バイエル ファーマセチカル コーポレーション | Rhoキナーゼ阻害剤としてのピリミジン誘導体 |
ATE381557T1 (de) * | 2002-01-23 | 2008-01-15 | Bayer Pharmaceuticals Corp | Rho-kinase inhibitoren |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
US7645878B2 (en) * | 2002-03-22 | 2010-01-12 | Bayer Healthcare Llc | Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
EP2280003B1 (de) * | 2002-07-15 | 2014-04-02 | Symphony Evolution, Inc. | Verfahren zur Herstellung von Rezeptorkinase-Modulatoren |
BR0313059B8 (pt) | 2002-07-29 | 2021-07-27 | Rigel Pharmaceuticals | composto, e, composição farmacêutica |
US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
BR0316487A (pt) | 2002-11-26 | 2005-10-11 | Pfizer Prod Inc | Método todo de tratamento da rejeição de transplantes |
PL376844A1 (pl) * | 2002-12-09 | 2006-01-09 | The Board Of Regents Of The University Of Texas System | Sposoby selektywnego hamowania kinazy tyrozynowej 3 z grupy Janus (JAK3) |
US7638122B2 (en) * | 2003-03-07 | 2009-12-29 | University Of South Florida | Stat3 antagonists and their use as vaccines against cancer |
GB0309850D0 (en) | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
US8309562B2 (en) * | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
NZ544472A (en) | 2003-07-03 | 2009-04-30 | Myriad Genetics Inc | Compounds and therapeutical use thereof |
GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
RS53109B (en) | 2003-07-30 | 2014-06-30 | Rigel Pharmaceuticals Inc. | 2,4 PIRIMIDINDIAMINE COMPOUNDS FOR USE IN TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES |
SI1667991T1 (sl) | 2003-09-16 | 2008-10-31 | Astrazeneca Ab | Kinazolinski derivati kot inhibitorji tirozin kinaze |
SI2392564T1 (sl) | 2003-09-26 | 2014-02-28 | Exelixis, Inc. | c-Met modulatorji in postopki uporabe |
GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
WO2005073224A2 (en) | 2004-01-23 | 2005-08-11 | Amgen Inc | Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer |
TW200536851A (en) | 2004-01-23 | 2005-11-16 | Amgen Inc | Compounds and methods of use |
EP1827434B1 (de) * | 2004-11-30 | 2014-01-15 | Amgen Inc. | Chinolin- und chinazolinanaloge und deren verwendung als medikamente zur krebsbehandlung |
JP2008526734A (ja) * | 2004-12-31 | 2008-07-24 | エスケー ケミカルズ カンパニー リミテッド | 糖尿及び肥満治療予防に有効なキナゾリン誘導体 |
US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
CA2592900A1 (en) | 2005-01-03 | 2006-07-13 | Myriad Genetics Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
RU2007140903A (ru) * | 2005-04-05 | 2009-05-20 | Фармакопия, Инк. (Us) | Производные пурина и имидазопиридина для иммуносупрессии |
US7884109B2 (en) * | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
JO2787B1 (en) * | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
WO2006133426A2 (en) | 2005-06-08 | 2006-12-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
JP2009508918A (ja) | 2005-09-20 | 2009-03-05 | アストラゼネカ アクチボラグ | 癌治療のためのerbB受容体チロシンキナーゼ阻害剤としての4−(1H−インダゾール−5−イル]アミノ)キナゾリン化合物 |
US20090281075A1 (en) * | 2006-02-17 | 2009-11-12 | Pharmacopeia, Inc. | Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
US7989459B2 (en) * | 2006-02-17 | 2011-08-02 | Pharmacopeia, Llc | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors |
ES2622493T3 (es) | 2006-02-24 | 2017-07-06 | Rigel Pharmaceuticals, Inc. | Composiciones y métodos para la inhibición de la ruta de JAK |
US7902187B2 (en) * | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
WO2008043031A1 (en) * | 2006-10-04 | 2008-04-10 | Pharmacopeia, Inc. | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
US7915268B2 (en) | 2006-10-04 | 2011-03-29 | Wyeth Llc | 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression |
EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
US20080119496A1 (en) * | 2006-11-16 | 2008-05-22 | Pharmacopeia Drug Discovery, Inc. | 7-Substituted Purine Derivatives for Immunosuppression |
EP2118075A1 (de) | 2007-02-06 | 2009-11-18 | Boehringer Ingelheim International GmbH | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
DE102008012435A1 (de) * | 2008-02-29 | 2009-09-03 | Schebo Biotech Ag | Neue Pharmazeutika, Verfahren zu ihrer Herstellung und ihre Verwendung in der Therapie |
EP2220078B1 (de) * | 2007-10-29 | 2013-05-22 | Amgen, Inc | Benzomorpholinderivate und anwendungsverfahren |
EA019709B1 (ru) | 2008-02-07 | 2014-05-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Спирогетероциклы и их применение в качестве лекарственных средств |
EP2265607B1 (de) | 2008-02-15 | 2016-12-14 | Rigel Pharmaceuticals, Inc. | Pyrimidin-2-aminverbindungen und ihre verwendung als inhibitoren von jak-kinasen |
US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
EA019973B1 (ru) | 2008-04-16 | 2014-07-30 | Портола Фармасьютиклз, Инк. | ИНГИБИТОРЫ Syk ПРОТЕИНКИНАЗ |
AU2009238590A1 (en) | 2008-04-22 | 2009-10-29 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
EA019183B1 (ru) | 2008-05-13 | 2014-01-30 | Астразенека Аб | Фумаратная соль 4-(3-хлор-2-фторанилино)-7-метокси-6-{[1-(n-метилкарбамоилметил)пиперидин-4-ил]окси}хиназолина |
WO2010015522A1 (de) | 2008-08-08 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
PT2384326E (pt) | 2008-08-20 | 2014-06-09 | Zoetis Llc | Compostos de pirrolo[2,3-d]pirimidina |
EA021367B1 (ru) | 2008-11-28 | 2015-06-30 | Кова Компани, Лтд. | Производное пиридин-3-карбоксамида |
CA2995880C (en) | 2009-01-16 | 2021-01-05 | Exelixis, Inc. | Processes for preparing n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
RU2012148246A (ru) | 2010-04-14 | 2014-05-20 | Эррэй Биофарма Инк. | 5, 7- замещенные-имидазо[1, 2-с]пиримидины как ингибиторы jak-киназ |
US9102625B2 (en) | 2010-11-01 | 2015-08-11 | Portola Pharmaceuticals, Inc. | Nicotinamides as JAK kinase modulators |
WO2013025628A1 (en) | 2011-08-15 | 2013-02-21 | Ligand Pharmaceuticals Incorporated | Janus kinase inhibitor compounds and methods |
CN103987713A (zh) | 2011-10-12 | 2014-08-13 | 阵列生物制药公司 | 5,7-取代的咪唑并[1,2-c]嘧啶 |
CA2856301C (en) | 2011-11-23 | 2020-10-06 | Portola Pharmaceuticals, Inc. | Pyrazine kinase inhibitors |
WO2014013014A1 (en) | 2012-07-18 | 2014-01-23 | Fundació Privada Centre De Regulació Genòmica (Crg) | Jak inhibitors for activation of epidermal stem cell populations |
EP2903970A4 (de) | 2012-10-08 | 2016-11-30 | Portola Pharm Inc | Substituierte pyrimidinylkinasehemmer |
HUE054371T2 (hu) | 2014-12-05 | 2021-09-28 | Array Biopharma Inc | 4,6-szubsztituált pirazolo[l,5-A]pirazinok mint janus kináz inhibitorok |
WO2017103932A1 (en) | 2015-12-17 | 2017-06-22 | Biokine Therapeutics Ltd. | Small molecules for inhibiting chemokine activity, a kinase activity and/or cancer cells growth |
WO2017103931A1 (en) | 2015-12-17 | 2017-06-22 | Biokine Therapeutics Ltd. | Small molecules against cancer |
WO2018041989A1 (en) | 2016-09-02 | 2018-03-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating refractory celiac disease type 2 |
US10759865B2 (en) | 2017-08-22 | 2020-09-01 | Eyal Levit | Treatment of diabetes mellitus |
KR20210132666A (ko) | 2019-02-25 | 2021-11-04 | 허난 메디노 파마슈티컬 테크놀로지 컴퍼니 리미티드 | Jak 억제제 화합물 및 그 사용 |
JP2022527972A (ja) | 2019-04-02 | 2022-06-07 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 前悪性病変を有する患者において癌を予測及び予防する方法 |
US20220202820A1 (en) | 2019-04-16 | 2022-06-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels |
BR112021022775A2 (pt) | 2019-05-15 | 2022-02-01 | Alonbio Ltd | Moléculas pequenas para tratamento do câncer, inibição da atividade da quimiocina e/ou indução da morte celular |
CN112707846B (zh) * | 2019-10-25 | 2023-04-21 | 成都伊诺达博医药科技有限公司 | 一种达克替尼关键中间体的制备方法 |
WO2023222565A1 (en) | 2022-05-16 | 2023-11-23 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3985749A (en) * | 1975-12-22 | 1976-10-12 | Eastman Kodak Company | Process for preparation of 4-aminoquinazoline |
JPS5538325A (en) | 1978-09-11 | 1980-03-17 | Sankyo Co Ltd | 4-anilinoquinazoline derivative and its preparation |
US4343940A (en) | 1979-02-13 | 1982-08-10 | Mead Johnson & Company | Anti-tumor quinazoline compounds |
US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5728536A (en) | 1993-07-29 | 1998-03-17 | St. Jude Children's Research Hospital | Jak kinases and regulation of Cytokine signal transduction |
US5712395A (en) * | 1992-11-13 | 1998-01-27 | Yissum Research Development Corp. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
US5792771A (en) | 1992-11-13 | 1998-08-11 | Sugen, Inc. | Quinazoline compounds and compositions thereof for the treatment of disease |
US5656643A (en) * | 1993-11-08 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
GB9510757D0 (en) * | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
US5705625A (en) | 1994-12-15 | 1998-01-06 | The Johns Hopkins University School Of Medicine | Nucleic Acid Encoding novel protein tyrosine kinase |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
DE69618587T2 (de) * | 1995-06-07 | 2002-08-29 | Sugen, Inc. | Chinazoline und pharmazeutische zusammensetzungen |
US5798374A (en) | 1995-06-07 | 1998-08-25 | Sugen Inc. | Methods of inhibiting phosphatase activity and treatment of disorders associated therewith |
AU6407696A (en) | 1995-07-07 | 1997-02-10 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Method of identifying inhibitors of the jak-stat signal transduction pathway |
GB9514265D0 (en) * | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
IL125686A (en) * | 1996-02-13 | 2002-11-10 | Zeneca Ltd | Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability |
WO1997032856A1 (en) * | 1996-03-05 | 1997-09-12 | Zeneca Limited | 4-anilinoquinazoline derivatives |
GB9607729D0 (en) | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
AU4851599A (en) * | 1998-06-30 | 2000-01-17 | Parker Hughes Institute | Method for inhibiting c-jun expression using jak-3 inhibitors |
MXPA01001893A (es) * | 1998-08-21 | 2002-04-24 | Parker Hughes Inst | Derivados de quinazolina. |
US6080747A (en) * | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
US20030149045A1 (en) * | 1999-08-20 | 2003-08-07 | Fatih M Uckun | Therapeutic compounds |
-
1999
- 1999-08-20 MX MXPA01001893A patent/MXPA01001893A/es unknown
- 1999-08-20 EP EP99943800A patent/EP1105378B1/de not_active Expired - Lifetime
- 1999-08-20 IL IL14143499A patent/IL141434A0/xx unknown
- 1999-08-20 WO PCT/US1999/019043 patent/WO2000010981A1/en active IP Right Grant
- 1999-08-20 KR KR1020017002230A patent/KR20010089171A/ko not_active Application Discontinuation
- 1999-08-20 DE DE69924500T patent/DE69924500T2/de not_active Expired - Fee Related
- 1999-08-20 CA CA002342503A patent/CA2342503A1/en not_active Abandoned
- 1999-08-20 AT AT99943800T patent/ATE292121T1/de not_active IP Right Cessation
- 1999-08-20 HU HU0103386A patent/HUP0103386A3/hu unknown
- 1999-08-20 JP JP2000566255A patent/JP2002523403A/ja active Pending
- 1999-08-20 US US09/378,093 patent/US6313129B1/en not_active Expired - Fee Related
- 1999-08-20 AU AU56827/99A patent/AU5682799A/en not_active Abandoned
-
2001
- 2001-02-21 NO NO20010887A patent/NO20010887L/no not_active Application Discontinuation
- 2001-03-19 US US09/812,098 patent/US6495556B2/en not_active Expired - Fee Related
- 2001-05-16 US US09/858,824 patent/US6469013B2/en not_active Expired - Fee Related
-
2003
- 2003-11-17 US US10/715,773 patent/US20060276491A9/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
NO20010887L (no) | 2001-04-23 |
HUP0103386A2 (hu) | 2002-04-29 |
US20010044442A1 (en) | 2001-11-22 |
AU5682799A (en) | 2000-03-14 |
KR20010089171A (ko) | 2001-09-29 |
MXPA01001893A (es) | 2002-04-24 |
US6313129B1 (en) | 2001-11-06 |
DE69924500T2 (de) | 2006-02-09 |
EP1105378B1 (de) | 2005-03-30 |
JP2002523403A (ja) | 2002-07-30 |
US20060276491A9 (en) | 2006-12-07 |
US6469013B2 (en) | 2002-10-22 |
US20040192711A1 (en) | 2004-09-30 |
EP1105378A1 (de) | 2001-06-13 |
IL141434A0 (en) | 2002-03-10 |
HUP0103386A3 (en) | 2002-07-29 |
US6495556B2 (en) | 2002-12-17 |
CA2342503A1 (en) | 2000-03-02 |
NO20010887D0 (no) | 2001-02-21 |
US20020042513A1 (en) | 2002-04-11 |
WO2000010981A1 (en) | 2000-03-02 |
WO2000010981A9 (en) | 2002-08-29 |
ATE292121T1 (de) | 2005-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69924500D1 (de) | Chinazolinderivate | |
GEP20053424B (en) | Pyrimidine-2,4,6-Trione Metalloproteinase Inhibitors | |
NO20014560L (no) | Quinasoliner og terapautisk anvendelse derav | |
EA200200768A1 (ru) | Соединения индазола, фармацевтические композиции и методы модуляции или ингибирования клеточной пролиферации | |
NO20100777L (no) | Kinazolinoner, slike forbindelser for anvendelse som medikament, farmasoytiske preparater inneholdende slike samt anvendelse av slike for fremstilling av medikament for behandling av sykdom | |
TR199900048T2 (xx) | Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler | |
DE60231439D1 (de) | Mitotische kinesinhemmer | |
BG101284A (en) | Compounds and methods for cancer treatment | |
DK1438052T3 (da) | Quinazolin-4-oner af inhibitorer som human phosphatidylinositol 3-kinase delta | |
NO20014303L (no) | JAK-3-inhibitorer for behandling av allergiske lidelser | |
UY25074A1 (es) | Inhibidores de la farnesil proteina transferasa | |
DE60329990D1 (de) | Mitotische kinesin-hemmer | |
IS6501A (is) | Pyrrólafleiður 2-indólínón prótín kínasa hindra | |
IS2114B (is) | Kínasólínafleiður til að meðhöndla æxli | |
IL127965A0 (en) | Pentafluorobenzenesulfonamide derivatives analogs thereof and pharmaceutical compositions containing the same | |
PA8606201A1 (es) | DERIVADOS DE PIRROLO[3,4-c) PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN | |
IL142066A0 (en) | Arylsulfonanilide urea derivatives and pharmaceutical compositions containing the same | |
ATE527254T1 (de) | Mit imidazol enthaltenden sekundären aminen substituierte benzopyran-derivate, deren herstellung und diese enthaltende pharmazeutische zubereitungen | |
UA84954C2 (ru) | Конденсированные пиримидоны, пригодные для лечения и профилактики злокачественного новообразования | |
UY28130A1 (es) | Compuestos de indazol y composiciones farmaceuticaspara inhibr proteinquinasas, y procedimientos para su uso. | |
BR0208447A (pt) | Inibidores de cinase dependente de ciclina como agente anticâncer | |
DE69426334D1 (de) | Parenterales Busulfan zur Behandlung von malignen Krankheiten | |
DE60033649D1 (de) | Verbindungen und therapeutische methoden | |
PT1235571E (pt) | Utilizacao de melatonina para o tratamento da alopecia androgenetica e difusa do tipo feminino | |
MXPA02010759A (es) | Derivados del acido (2-oxindol-3-ilidenil) acetico y su uso como inhibidores de la proteina quinasa. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |